Xaliproden: SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene.
Xaliproden [SR 57746A, xaliprodene; Xaprila] is a compound that mimics the effects of nerve growth factor and is also a serotonin 5-HT1A receptor agonist. The drug was originated by Sanofi, and in mid-1999, Sanofi merged with Synthélabo to form Sanofi-Synthélabo. Phase III trials have been completed in patients with amyotrophic lateral sclerosis in Europe, the US and Canada. Xaliproden is at the phase II stage of clinical development for amyotrophic lateral sclerosis in Japan, where it also has orphan drug status for this indication.
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009281:Naphthalenes / Q000494:pharmacology* / Q000627:therapeutic use; D009965:Orphan Drug Production; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use
D009281:Naphthalenes; D011725:Pyridines; D017366:Serotonin Receptor Agonists; D044282:Receptor, Serotonin, 5-HT1A; C462299:xaliproden